The Effect of Dienogest vs. Norethindrone Acetate Treatment in Endometriosis
CompletedNot applicableNCT05476172
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This randomized controlled study aims to investigate the efficiency of medical treatment modalities in endometriosis patients. The study protocol involves two arms. (Dienogest Group and Noretindrone Acetate Group). The patients diagnosed with endometriosis are randomized depending on their protocol ids. The Dienogest group is prescribed 5 mg dienogest per day and neta group is prescribed 5 mg neta per day. The pain scores will be analyzed six months and twelve months after treatment.
Study details
- Official title
- The Effect of Dienogest vs. Norethindrone Acetate Treatment in Endometriosis
- Conditions
- Interventions
- Drug: Dienogest Pill
- Drug: Norethindrone Acetate
- Sponsor
- Uludag University
- Start date
- 2021-04-01
- Primary completion
- 2023-05-30
- Sex
- Female
- Age range
- from 18 Years to 40 Years
- Results posted
- No results posted in this snapshot
- Countries
- Turkey (Türkiye)
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * 18 - 40 years aged women diagnosed with endometriosis Exclusion Criteria: * malignancy * need for surgery * pregnancy desire
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT05476172